本文選題：帕金森病　切入點(diǎn)：普拉克索　出處：《中國醫(yī)藥指南》2016年35期

【摘要】：目的探討帕金森病患者經(jīng)多巴胺受體激動劑普拉克索治療的臨床效果及安全性。方法回顧性分析我院2013年5月至2015年5月收治的60例帕金森病患者的臨床資料,60例帕金森病患者隨機(jī)劃分為觀察組與對照組,兩組各30例。觀察組30例患者給予巴胺受體激動劑普拉克索治療,對照組30例患者給予帕羅西汀聯(lián)合美多芭治療。選取漢密頓抑郁量表、統(tǒng)一帕金森評定量表的第Ⅲ部分進(jìn)行療效評定,每4周評定一次臨床治療效果;選取不良反應(yīng)量表于第12周末對治療安全性進(jìn)行評定。對比觀察組患者與對照組患者臨床治療效果及安全性。結(jié)果觀察組與對照組第4周末、第8周末的HAMD評分、UPDRSⅢ總分無明顯差異,不具備統(tǒng)計(jì)學(xué)意義(P0.05);觀察組第12周末HAMD評分、UPDRSⅢ總分明顯優(yōu)于對照組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05);觀察組不良反應(yīng)發(fā)生率明顯低于對照組,兩組差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論帕金森病患者經(jīng)多巴胺受體激動劑普拉克索治療的臨床效果十分顯著,安全性好,值得在臨床治療中推廣應(yīng)用。
[Abstract]:Objective to investigate the clinical efficacy and safety of Parkinson's disease treated with dopamine receptor agonist Praxol. Methods the clinical data of 60 patients with Parkinson's disease from May 2013 to May 2015 were retrospectively analyzed. Patients with Parkinson's disease were randomly divided into observation group and control group. There were 30 cases in each group. 30 patients in the observation group were treated with praquisol, and 30 patients in the control group were treated with paroxetine combined with medoba. The curative effect was evaluated in the third part of the unified Parkinson's scale, and the clinical treatment effect was evaluated every 4 weeks. Adverse reaction scale was selected to evaluate the safety of the treatment at the end of the 12th week. The clinical efficacy and safety of the patients in the observation group and the control group were compared. Results at the end of the 4th week, the patients in the observation group and the control group were assessed. At the end of the 8th week, there was no significant difference in the total score of HAMD 鈪，

本文編號：1656618